A comparative analysis of intravesical sodium hyaluronate monotherapy and its combination with oral chondroitin sulfate in patietns with bladder pain syndrome/intersticial cystitis
- Authors: Aboyan I.A1, Aboyan V.E1, Pavlov S.V1, Zin’kovskaya O.V1, Pavlov D.S2
-
Affiliations:
- MBUZ Clinical and diagnostic Center “Zdorovie”
- Rostov State Medical University
- Issue: No 1 (2019)
- Pages: 35-39
- Section: Articles
- URL: https://journals.eco-vector.com/1728-2985/article/view/296454
- DOI: https://doi.org/10.18565/urology.2019.16.35-39
- ID: 296454
Cite item
Open Access
Access granted
Abstract
Aim. It is established that intravesical sodium hyaluronate and chondroitin sulfate has high efficacy in patients with bladder pain syndrome/interstitial cystitis (BPS/IC). Currently, an oral form of chondroitin sulfate is also available. The aim of study was to compare the efficacy of intravesical hyaluronic acid monotherapy and long-term oral chondroitin sulfate in combination with intravesical therapy in patients with BPS/IC. Materials and methods. A total of 59 patients with BPS/IC were randomized in two groups. In Group 1, 30 women (mean age 57.1 years) received viscoelastic solution of sodium hyaluronate 50 ml 1 time per week for 12 weeks as intravesical monotherapy. In Group 2 (n=29), patients were prescribed to complex therapy, which included the similar intravesical therapy combined with chondroitin sulfate in a dose 0.39 g, 2 capsules 3 times a day, also for 12 weeks. All patients completed visual analogue scale (VAS), interstitial cystitis symptom index (ISCI), interstitial cystitis problems index (ICPI) and voiding diary before and 1 week after the start of therapy. In all cases a cystoscopy and urodynamic study were performed in order to exclude other bladder pathologies. Results. At baseline, a mean VAS score in both groups was 7 points, a mean ISCI score was 17 points in Group 1 and 18 points in Group 2 (p>0.1). The mean ICPI score in both groups was 15 points. A frequency of urination in Group 1 and 2 was 11.4 and 11.6 per day, respectively (p>0,1). A mean volume ofurination was 138+24.6 and 131+18.6 мл, respectively. After 12 weeks of therapy there was significant improvement of VAS, ICSI and ICPI scores in both groups, as well as frequency and volume of urination, but in Group 2 an improvement in almost all parameters studied, except for the volume of urination, was more pronounced. Conclusion. The combined therapy of BPS/IC with intravesical hyaluronic acid and oral chondroitin sulfate provides significantly better results in comparison with intravesical hyaluronic acid as monotherapy.
Full Text
About the authors
I. A Aboyan
MBUZ Clinical and diagnostic Center “Zdorovie”
Email: aboyan@center-zdorovie.ru
MD, professor, honored doctor of the Russian Federation, chief physician
V. E Aboyan
MBUZ Clinical and diagnostic Center “Zdorovie”
Email: v-aboyan@yandex.ru
Ph.D., urologist
S. V Pavlov
MBUZ Clinical and diagnostic Center “Zdorovie”
Email: pavlovsvzdorovie@yandex.ru
Ph.D., urologist, Head of the Department of Organizational and Methodical work
O. V Zin’kovskaya
MBUZ Clinical and diagnostic Center “Zdorovie”urologist
D. S Pavlov
Rostov State Medical University
Email: pavlovdmitry94@gmail.com
student
References
- Engeler D., Baranowski A. P., Borovicka J. et al. EAU Guidelines on Chronic Pelvic Pain. 2016. Available online at: https://uroweb.org/ guideline/chronic-pelvic-pain/
- Nordling J., Fall M., Hanno P. Global concepts of bladder pain syndrome (interstitial cystitis). World J Urol. 2012;30:457-464.
- Bogart L.M., Suttorp M.J., Elliott M.N., Clemens J.Q., Berry S.H. Prevalence and correlates of sexual dysfunction among women with bladder pain syndrome/interstitial cystitis. Urology. 2011;77:576-580.
- Hanno P.M. Bladder pain syndrome (interstitial cystitis) and related disorder; in Wein A.J., Kavoussi L.R., Novick A.C., Partin A.W., Peters C.A. (eds). Campbell-Walsh urology. 11th ed. Philadelphia, Saunders. 2016;1:334-370.
- Konkle K.S., Berry S.H., Elliott M.N. et al. Comparison of an interstitial cystitis/bladder pain syndrome clinical cohort with symptomatic community women from the RAND Interstitial Cystitis Epidemiology study. J. Urol. 2012;187:508.
- Moldwin R.M., Sant G.R. Interstitial cystitis: a pathophysiology and treatment update. ClinObstet Gynecol. 2002;45:259-272.
- Игнашов Ю.А., Кузьмин И.В., Слесаревская М.Н. Синдром болезненного мочевого пузыря: исторические аспекты. История медицины. 2016;6(3):5-10
- Hurst R.E. Structure, function, and pathology of proteoglycans and glycosaminoglycans in the urinary tract. World J. Urol. 1994;12:3.
- Cervigni M., Natale F., Nasta L., Mako A. Intravesical hyaluronic acid and chondroitin sulphate for bladder pain syndrome/interstitial cystitis: longterm treatment results. Int Urogynecol J. 2012;23:1187-1192.
- Morales A., Emerson L., Nickel J.C., Lundie M. Intravesical hyaluronic acid in the treatment of refractory interstitial cystitis. J. Urol. 1996;156:45-48.
- Gülpinar Ö., Esen B., Kayis A., Gökqe M.I., Süer E. Clinical comparison of intravesical hyaluronic acid and chondroitin sulfate therapies in the treatment of bladder pain syndrome/interstitial cystitis. Neurourol Urodyn. 2018;37(1):257-262. doi: 10.1002/nau.23284. Epub 2017 May 8.
- Hurst R.E. Structure, function, and pathology of proteoglycans and glycosaminoglycans in the urinary tract. World J. Urol. 1994;12:3.
- Hanno P., Baranowski A., Fall M. et al. Painful bladder syndrome (including interstitial cystitis). In: Abrams PH, Wein AJ, CardozoL, eds. Incontinence (3rd ed.) Paris: Health Publications Limited. 2005: 1456-1520.
- Steinhoff G., Ittah B., Rowan S. The efficacy of chondroitin sulfate 0.2% in treating interstitial cystitis. Can J. Urol. 2002;9:1454.
- Porru D. et al., Impact of intravesical hyaluronic acid and chondroitin sulfate on bladder pain syndrome/interstitial cystitis. IntUrogynecol J. 2012;23(9):1193-199. doi: 10.1007/s00192-011-1546-5.
- Cervigni M. et al. A randomized, open-label, multicenter study of the efficacy and safety of intravesical hyaluronic acid and chondroitin sulfate versus dimethyl sulfoxide in women with bladder pain syndrome/ interstitial cystitis. NeurourolUrodyn. 2017;36(4): 1178- 1186. doi: 10.1002/nau.23091.
- Torella M., Del Deo F., Grimaldi A., Iervolino S.A., Pezzella M., Tammaro C., Gallo P., Rappa C., De Franciscis P., Colacurci N. Efficacy of an orally administered combination of hyaluronic acid, chondroitin sulfate, curcumin and quercetin for the prevention of recurrent urinary tract infections in postmenopausal women. Eur J. Obstet Gynecol Reprod Biol. 2016;207:125-128.
- Theoharides T.C., Kempuraj D., Vakali S., Sant G.R. Treatment of refractory interstitial cystitis/painful bladder syndrome with CystoProtek -an oral multi-agent natural supplement. Can J. Urol. 2008;15(6):4410-14.
- Hurst R.E., Zebrowski R. Identification of proteoglycans present at high density on bovine and human bladder luminal surface. J. Urol. 1994;152:1641.
Supplementary files
